This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

ImmunoGen Is Over-Valued

Stocks in this article: IMGN RHHBY GSK

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

BOSTON ( TheStreet) -- ImmunoGen (IMGN), with a market value hovering around $1.2 billion, is significantly over-valued.

I'm sorry for being a Debbie Downer. I like the guys running ImmunoGen. It's a feel-good story -- a small drug delivery technology company done good with a nice run in the stock price. Unfortunately, the numbers don't lie: ImmunoGen only gets a tiny 5% royalty on sales of the breast cancer drug T-DM1 being developed by the Genentech unit of Roche (RHHBY).

Even if T-DM1 becomes a blockbuster cancer drug, ImmunoGen's stake is tiny, meaning there is no fundamental rationale for the stock to be even close to $15..

I understand that traders are bidding up ImmunoGen on today's announcement from Genentech about the positive T-DM1 results from the second-line breast cancer trial known as "EMILIA." At some point, numbers do matter -- a point "investors" should keep in mind.

Let's do some math. Genentech is developing T-DM1 as a next-generation version of Herceptin, which generated sales of roughly $5 billion last year. I'm going to be incredibly generous and assume that T-DM1 replaces Herceptin. Never mind that T-DM1 will be approved next year only for second-line breast cancer or that expanding into first-line breast cancer (Herceptin's current role) could take another two or three years.

So, I'm projecting $5 billion in T-DM1 sales by the end of 2017, or four years after initial approval. A tremendous success story!

Immunogen gets 5% of that $5 billion in 2017, or $250 million.

Applying a multiple of 7 times sales, discounted back to the present, puts ImmunoGen's enterprise value at about $900 million, or roughly the company's current value.

Like I said, you really need to stretch the bounds of reality to make ImmunoGen's current valuation work. Even if you want to ascribe some value to its pipeline outside of TDM-1 (although not sure it deserves much at this point given the stilted clinical progress), the stock is too richly priced.

Enough fantasy thinking. Let's be more realistic. If T-DM1 is approved next year it will compete against Glaxo's (GSK) Tykerb as a second-line breast cancer therapy. Tykerb's worldwide sales in 2011 were $372 million.

If we use round numbers and assume T-DM1 totally displaces Tykerb in a couple of years, that's only worth $20 million in royalty revenue to ImmunoGen.

As you can see, the math doesn't work too well in ImmunoGen's favor. And that covers any takeout scenario you might want to conjure up as well. Roche owes so little to ImmunoGen for TDM-1 that it makes more financial sense to pay the royalty ever year -- forget about forking over a premium or even current market value for the entire company.

Happy trading.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs